I understand just as much as you by reading your earlier posts, not an expert by any means but spent more time on it than I would have liked.
I can write whatever I want as long as I don't brake forum rules, dude, so I suggest you get down from your high horse, you fanboys are just incredible!
The company is diluting all shareholder's worth into nothing, you have to buy about 20% of your share count each year, in order to maintain your % of the company! I refuse to do that, I am done buying as much as a single share more.
Why are the company presenting new data from an old P1 trial? And D not L? Odd man. They should be concentrating about getting L over the line instead.
Why is that approval dragging out for such a long time, I don't believe it's manufacturing as some hinted.
The links I posted got me even more worried, Google don't seem to "know" anything about NWBO and DC-Vax.
Why are Harvard and Yale concentrating about developing new personalized cancer vaccines when we got DC-Vax, Huh? They are maybe not interested and think they can make something that's better or Linda P is impossible to work with (no partners over all those years!)? It can only be one of the 3, so which is it?
FDA's new rapid approval politics could move them very quickly forward, not spending decades on it.
I come to realize that my investment here is maybe lost. If I sell now, I'II get less than 1/2 of my investment back, LOL, so I stay until approval or refusal.
Thankfully, my investments are spread out so I can walk away with my shirt on.
Market Data 
Markets 
AI
